YENİ TANI DİYABET HASTALARINDA İNFLAMASYON

Year 2023, , 143 - 147, 28.02.2023

Orkun Sarıçam

https://doi.org/10.53446/actamednicomedia.1211545

Cited By: 1

Abstract

Amaç: Tip 2 diyabetes mellutus (T2DM), inflamasyonun indüklediği düşünülen, tüm diyabetlilerin %90-95’ini oluşturan prevelansı giderek artan kronik bir hastalıktır. Bu çalışmada yeni tanı almış T2DM olan hastalarda inflamasyon parametrelerini ve bu parametrelerin kan grupları ile ilişkisini araştırmayı amaçladık.
Yöntem: Bu çalışmaya 80 yeni tanı almış T2DM hastası, 80 sağlıklı gönüllü dahil edildi. Hasta ve kontrol grubunun demografik özellikleri, vücut kitle indeksleri (VKİ), biyokimya, hemogram, C-reaktif proteini (CRP) ve kan grupları kayıt edilerek gruplar arasında karşılaştırıldı.
Bulgular: Yeni tanı alan T2DM hastalarının yaş ortalaması 51,64’dü ve hastaların %53,8’i erkekti. T2DM hastaların beyaz kan hücresi (BKH), nötrofil, lenfosit, platelet, monosit, monosit/HDL oranı (MHO), sistemik immün-inflamatuar indeks (Sİİ) ve CRP düzeyleri kontrol grubundan istatistiksel olarak anlamlı derecede yüksek saptandı. (p<0,05) T2DM’li hastalarda kan grubu B olanların platelet değerleri, kan grubu O olan grupdan istatistiksel olarak anlamlı derecede yüksek saptandı. (p=0,022)
Sonuç: Yeni tanı T2DM hastalarında inflmasyonu gösteren hematolojik parametrelerin ve MHO ve Sİİ oranlarındaki yüksekliğinin, hastalarda komplikasyon gelişmeden kronik sistemik enflamasyonun varlığını gösterdiğini, prediyabetik hastalarda tanıda ve koruyucu tedaviye başlamada yol gösterici olabileceğini düşünüyoruz.

Keywords

Tip 2 diyabetes mellutus, inflamasyon, kan grubu

Supporting Institution

yok

INFLAMMATION IN NEWLY DIAGNOSED DIABETES PATIENTS

Abstract

Objective. Type 2 diabetes mellitus (T2DM) is a chronic disease with an increasing prevalence, accounting for 90-95% of all diabetics. It is considered that the disease is induced by inflammation. In this study, we aimed to investigate the inflammation parameters and the relationship of these parameters with blood groups in newly diagnosed T2DM patients.
Methods. The study included 80 newly diagnosed T2DM patients and 80 healthy volunteers. Demographic characteristics, body mass indexes (BMI), biochemistry and hemogram test results, C-reactive protein (CRP) values, and blood groups of the patient and control groups were recorded and compared between the groups.
Results. The mean age was 51.64 years and 53.8% of the patients were male in the newly diagnosed T2DM group. The counts of white blood cells (WBC), neutrophils, lymphocytes, platelets, and monocytes, the values of the monocyte/HDL ratio (MHR) and the systemic immune-inflammatory index (SII), and the CRP levels of T2DM patients were statistically significantly higher than those of the control group (p<0.05). Of the T2DM patients, the platelet counts were statistically significantly higher in the blood type B group compared to the blood type O group (p=0.022).
Conclusion. We think that the hematological parameters of inflammation and the high MHR and SII ratios indicate the presence of chronic systemic inflammation in newly diagnosed T2DM patients before the development of complications. Therefore, these parameters may guide the diagnosis and preventive treatment in prediabetic patients.

Keywords

Type 2 diabetes mellitus, inflammation, blood group.

References

• 1. American Diabetes A 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care. 2019;42:13–28. doi.org/10.2337/ dc19-S002
• 2. Oever IAM, Raterman HG, Nurmohamed MT, Simsek S. Endothelial Dysfunction, Inflammation, and Apoptosis in Diabetes Mellitus. Mediators Inflamm. 2010;2010:792393. doi:10.1155/2010/792393
• 3. Biondi-Zoccai GG, Abbate A, Liuzzo G, Biasucci LM. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol. 2003;41:1071–1077. doi:10.1016/s0735-109 7(03)00088-3
• 4. Böni-Schnetzler M, Thorne J, Parnaud G, et al. Increased interleukin (IL)-1β messenger ribonucleic acid expression in β-cells of individuals with type 2 diabetes and regulation of IL-1β in human islets by glucose and autostimulation, J Clin Endocrinol Metab. 2008;93 (10):4065–4074. doi:10.1210/jc.2008-0396
• 5. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. Journal of Clinical Endocrinology and Metabolism, vol. 2004;89(2):463–478. doi:10.1210/jc. 2003-030723
• 6. Crook M. Type 2 diabetes mellitus: a disease of the innate immune system? An update. Diabet Med. 2004;21(3):203–207. doi:10.1046/j.1464-5491.2003.010 30.x
• 7. Duman TT, Aktas G, Atak BM, Kocak MZ, Erkus E, Savli H. Neutrophil to lymphocyte ratio as an indicative of diabetic control level in type 2 diabetes mellitus. Afr Health Sci. 2019;19:1602–1606. doi:10.4314/ahs.v19i1.35
• 8. Jaaban M, Zetoune AB, Hesenow S, Hessenow R. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as novel risk markers for diabetic nephropathy in patients with type 2 diabetes. Heliyon. 2021;7(7): e07564. doi:10.1016/j.heliyon.2021.e07564
• 9. Ewald DR, Sumner SC. Blood type biochemistry and human disease. Wiley Interdiscip Rev Syst Biol Med. 2016;8:517–35. doi:10.1002/wsbm.1355
• 10. Liumbruno GM, Franchini M. Beyond immune haematology: The role of the ABO blood group in human diseases. Blood Transfus. 2013;11:491–9. doi:10.2450/ 2013.0152-13
• 11. Bahar A, Asadian L, Abediankenai S, Namazi SS, Kashi Z. Coronary heart disease and ABO blood group in diabetic women: a case-control study. Scientific Reports. 2019;9(1):1–6. doi:10.1038/s41598-019-43890-4
• 12. Jankowski JA. Inflammation and Gastrointestinal Cancers: Springer Science & Business Media, Springer, Berlin, Heidelberg, 2011.
• 13. Feng JF, Chen S, Yang X. Systemic immune inflammation index (SII) is a useful prognostic indicator for patients with squamous cell carcinoma of the esophagus. Medicine (Baltimore). 2017;96(4):e5886. doi:10.1097/MD.000000 0000005886
• 14. Wu Y, Ding Y, Tanaka Y, Zhang W. Risk Factors Contributing to Type 2 Diabetes and Recent Advances in the Treatment and Prevention. Int J Med Sci. 2014;11(11):1185–1200. doi:10.7150/ijms.10001
• 15. Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. Endocr Rev. 2016;37(3):278–316. doi:10.1210/er.2015-1137
• 16. Gkrania-Klotsas E, Ye Z, Cooper AJ, et al. Differential White Blood Cell Count and Type 2 Diabetes: Systematic Review and Meta-Analysis of Cross-Sectional and Prospective Studies. PLoS One. 2010;5(10):e13405. doi:10.1371/ journal.pone.0013405
• 17. Zhang H, Yang Z, Zhang W, et al. White blood cell subtypes and risk of type 2 diabetes. J Diabetes Complications. 2017;31(1):31-37. doi:10.1016/j.jdiacomp. 2016.10.029
• 18. Elimam H, Abdulla AM, Taha IM. Inflammatory markers and control of type 2 diabetes mellitus. Diabetes Metab Syndr. 2019;13(1):800-804. doi:10.1016/j.dsx.2018.11. 061
• 19. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001:18;286 (3):327-34. doi: 10.1001/jama.286.3.327
• 20. Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018;17:121. doi:10.1186/s12933-018-0763-3
• 21. Pretorius E. Platelets as Potent Signaling Entities in Type 2 Diabetes Mellitus. Trends Endocrinol Metab. 2019;30(8):532-545. doi:10.1016/j.tem.2019.05.003
• 22. Maravilla Domínguez MA, Zermeño González ML, Zavaleta Muñiz ER, et al. Inflammation and atherogenic markers in patients with type 2 diabetes mellitus. Clin Investig Arterioscler. 2021;2;S0214-9168(21)00076-0. doi:10.1016/j.arteri.2021.03.006
• 23. Cardoso CRL, Leite NC, Salles GF. Importance of hematological parameters for micro- and macrovascular outcomes in patients with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study. Cardiovasc Diabetol. 2021;20(1):133. doi:10.1186/s12933-021-013 24-4
• 24. Wang J, Zhou D, Dai Z, Li X. Association Between Systemic Immune-Inflammation Index and Diabetic Depression. Clin Interv Aging. 2021;16:97–105. doi:10.2147/CIA.S285000
• 25. Dodiya D, Patel A, Jadeja J. A ssociation of ABO blood group with diabetes mellitus. International Journal of Basic and Applied Physiology. 2016;5(1):63–66. doi: 10.1155/2020/2535843
• 26. Legese B, Abebe M, Alebachew Fasil A. Association of ABO and Rh Blood Group Phenotypes with Type 2 Diabetes Mellitus at Felege Hiwot Comprehensive Referral Hospital Bahir Dar, Northwest Ethiopia. Int J Chronic Dis. 2020;2020:2535843. doi: 10.1155/2020/2535843
• 27. Sharjeel S, Wasi M, Jafri A, et al. Cureus.The Correlation Between Blood Group Type and Diabetes Mellitus Type II: A Case-Control Observational Study From Pakistan. Cureus. 2021;13(11):e19898. doi: 10.7759/cureus.19898
• 28. Höglund J, Karlsson T, Johansson T, Ek WE, Johansson Å. Characterization of the human ABO genotypes and their association to common inflammatory and cardiovascular diseases in the UK Biobank. Am J Hematol. 2021;96(11):1350-1362. doi: 10.1002/ajh.26307